| Today’s Big NewsAug 21, 2024 |
|
September 9-12, 2024 | Philadelphia, PA Join us at Digital Pharma East, the leading event for digital innovation in the pharmaceutical industry. Dive into key topics including Digital Marketing, Data & Analytics, and Patient Engagement. Learn from industry experts, network with peers, and explore cutting-edge strategies to drive your digital initiatives forward. The clock is TICKING! Secure Your Pass!
|
|
| By Heather Landi Roche says it's actively working with its partners to enhance mpox laboratory capacity worldwide to combat the outbreak. |
|
|
|
By Kevin Dunleavy Gaining FDA approval for its epinephrine nasal spray came nearly a year later than expected for ARS Pharmaceuticals. But the San Diego drugmaker is now poised for an October launch and a “blue sky opportunity,” according to the team of analysts at Leerink Partners. |
By Nick Paul Taylor The FDA has thrown a wrench in Regeneron’s plans to challenge Johnson & Johnson and Pfizer in a blood cancer market, hitting the Big Biotech with a complete response letter over issues at a third-party manufacturer. |
By Nick Paul Taylor BioMarin Pharmaceutical is shaking up its leadership team, raiding Amgen for an R&D chief to replace a departing company veteran and pulling off the coup of signing a high-profile former Roche dealmaker. |
|
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
By Zoey Becker A multi-employer health benefit plan in Illinois accused the drugmaker of scheming with pharmacy benefit managers to keep its Tecfidera in a more favorable spot on their formularies. |
By Ben Adams Specialty pharmacy and drug infusion company BioTek reMEDys, in honor of August being International Autoinflammatory Awareness Month, is calling for “enhanced education and awareness” around these types of diseases. |
By Emma Beavins PitchBook released its Q2 findings for the medical technology industry. The report notes that Tempus AI’s IPO and Insightec, BillionToOne funding rounds bode well for the sector. |
By Fraiser Kansteiner Following several years of legal back-and-forth, AMAG Pharmaceuticals has lost its bid to claim insurance coverage for a manufacturing snafu that took place at a Pfizer facility back in 2017. |
By Gabrielle Masson BridgeBio Pharma is once again spinning out a chunk of its pipeline, this time offloading a handful of early-stage genetic disease programs to a new company called GondolaBio. |
By Kevin Dunleavy A survey of more than 800 biopharma executives shows that sustainability is becoming an increasingly important priority but that companies are struggling to achieve it and as a result are putting their business at risk. |
By Darren Incorvaia On the heels of a June paper showing a small molecule's ability to declutter pathological protein buildups in the brain, researchers from the University of California, San Diego and the University of Pennsylvania have received a $6.9 million grant from the National Institute on Aging to prepare the drug for clinical trials. |
By Nick Paul Taylor Supreme Group has continued its private equity-backed acquisition spree, inking its third takeover in 14 months by snapping up the U.K.-based marketing and public relations agency BioStrata. |
By Heather Landi Cancer diagnostics startup PreciseDx picked up $20.7 million in series B funding as it ramps up commercialization efforts for its AI-based breast cancer risk assessment. |
By Nick Paul Taylor Republica Havas is expanding in North America, appointing three executives to lead a push to bring its cross-cultural approach to marketing to New York City. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “The Top Line,” Fierce executive editor Eric Sagonowsky chats with Angus Liu about his feature story on the three TROP2 front-runners. |
|
|---|
|
|
|
Thursday, September 12, 2024 | 10am ET / 7am PT Nitrosamines, potent carcinogens, have prompted stringent regulations for their detection and control in various products. With regulatory bodies demanding robust analytical methods and risk assessments, pharmaceutical and medical devices manufacturers must stay on top of the current regulatory landscape and compliance strategies. Register now for access to the key insights you need to know. |
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
